Publications by authors named "Kristine Storey"
Article Synopsis
- Immunogenicity testing helps understand the immune response to protein therapies, and neutralizing antibody (NAb) assays are key to characterizing anti-drug antibody responses.
- A group of NAb assay experts has created standardized reporting recommendations to streamline communication and facilitate regulatory submissions.
- The document outlines essential components for NAb sample analysis reports, though it does not cover the interpretation of immunogenicity data related to safety and efficacy.
First-generation antibody-drug conjugates (ADC) are heterogeneous mixtures that have shown clinical benefit, but generally exhibited safety issues and a narrow therapeutic window due, in part, to off-target toxicity caused by ADC instability. ARX788 is a next-generation, site-specific anti-HER2 ADC that utilizes a unique nonnatural amino acid-enabled conjugation technology and a noncleavable Amberstatin (AS269) drug-linker to generate a homogeneous ADC with a drug-to-antibody ratio of 1.9.
View Article and Find Full Text PDFExogenous angiotensin II increases mean arterial pressure in patients with catecholamine-resistant vasodilatory shock (CRVS). We hypothesized that renin concentrations may identify patients most likely to benefit from such therapy. To test the kinetic changes in renin concentrations and their prognostic value in patients with CRVS.
View Article and Find Full Text PDF